IMR Press / EJGO / Volume 23 / Issue 5 / pii/2002207

European Journal of Gynaecological Oncology (EJGO) is published by IMR Press from Volume 40 Issue 1 (2019). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on as a courtesy and upon agreement with S.O.G.

Original Research

Gains and losses of glycoprotein CD44 and secretory component expression in endometrial hyperplasia and neoplasia

Show Less
1 Department of Cytology, Regional Hospital of Alexandroupolis, Greece
2 Department of Medical Physics, Democritus University of Thrace, Greece
3 Department of Histology-Embryology, Democritus University of Thrace, Greece
4 Department of Pathology, General Hospital of Drama, Greece
Eur. J. Gynaecol. Oncol. 2002, 23(5), 453–456;
Published: 10 October 2002

CD44 is an adhesion molecule, which binds hyaluronic acid and participates in a number of cell-cell interactions, including lymphocyte homing. The CD44 antigen is expressed on approximately 90% of lymphocytes, monocytes, granulocytes, and, in lower amounts on thymocytes, fibroblasts, and erythrocytes. Platelets lack CD44. In non-haematopoietic tissues, CD44 is widely distri­buted. The secretory component is isolated from human colostrum and is of help in more precise grading of endometrial carcinoma. In this study we examined CD44 and secretory component expression in adenomatous hyperplasia, atypical adenomatous hyper­plasia and well-differentiated adenocarcinoma (cribriform pattern). The results showed decreased expression of CD44 and increa­sed expression of secretory component as the lesion progressed to malignancy.

Glygoprotein CD44
Endometrial hyperplasia
Endometrial neoplasia
Back to top